A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Status:
Completed
Trial end date:
2009-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess systemic exposure of a new foam formulation of
tazarotene, 0.1% compared with Tazorac Gel, 0.1%. The study design and dosing regimen are
based on previous clinical studies with Tazorac Gel and Tazorac Cream.